REASONS TO INVEST
TriAgenics has developed a solution to a significant problem in the dental industry. Our Zero3 TBA technology offers a minimally invasive, high-precision procedure that is designed to eliminate the need for wisdom teeth removal and the associated pain, cost, and recovery time.
Total U.S. expenditures associated with extracting wisdom teeth and treating wisdom tooth problems are estimated to be more than $3 billion per year. We have calculated our Total Addressable Market (TAM) to be greater than $2.5 billion annually for Zero3 TBA products.*
We have previously raised more than $7.5 million in capital, including Series A1 and A2 preferred stock offerings. TriAgenics has established a solid IP position that includes 13 U.S. patents and a growing number of international patents in Australia, Canada, and Mexico. Our founder is an experienced dentist who has successfully launched 3 startups, which are still in operation today. Our Zero3 TBA technology has grabbed the attention of many oral surgeons and pediatric specialists.
TEAM
Leigh Colby • President, CEO, Corporate Secretary, and Director
Read More
David Paul Watson • Director & Chief of Operations
Read More
John Joseph Chopack Jr • Board Member
Prior to joining Neoss, John was a Principal and founding partner of Inspiros Ventures. John managed the day-to-day operations of Inspiros and was responsible for investment origination, portfolio company management, and investor relations. Johnhas 20 years of experience in private equity/venture capital investing in medtech companies. As a General Partner at HealthpointCapital, a $800 million AUM medtech-focused private equity firm, John played an integral role in the firm’s most profitable investments – Nexa Orthopedics, BioHorizons, and Blue Belt Technologies. These investments brought significant advances to the healthcare field and provided top quartile returns to investors.
Prior to his career in venture capital, John was an orthopedic sales representative for Wright Medical and Encore Orthopedics. Following his experience as an orthopedic sales representative, John worked on Wall Street with Investec and Techvest as a medtech analyst.
John has been recognized as a “40 under 40 Medtech Innovator” by Medical Device and Diagnostic Industry Magazine.
John received a BA from Lafayette College and an MBA from Fordham University Gabelli School of Business.
Read More
the pitch
TriAgenics has developed Zero3 TBA, a minimally invasive dental procedure designed for children ages 6-12 in order to prevent wisdom teeth from ever forming. All R&D is completed with 100% success in preventing tooth formation in animal studies. We are now preparing to apply for FDA 510(k) clearance. Assuming we receive clearance, we then plan to conduct human clinical trials in order to have specific safety data to present before going to market. Following FDA clearance, our goal is to enter the dental market with first sales in 2025. We have previously raised $7.5 million in capital and have established a solid IP position, including 13 U.S. patents and a growing number of international patents. Our founder is an experienced dentist who has successfully launched 3 startups in the past. Zero3 TBA technology has already garnered interest from oral surgeons and pediatric specialists.
Overview
TriAgenics' Zero3 TBA Technology Offers Surgery-Free Prevention of Wisdom Teeth
TriAgenics has developed a technology called Zero3 TBA that has the potential to revolutionize how the dental industry treats wisdom teeth. Zero3 TBA is a minimally invasive procedure designed for kids ages 6-12 in order to prevent wisdom teeth from ever forming. Zero3 TBA will be quick and is expected to have no significant recovery time or significant complications. With a 100% success rate in animal trials, TriAgenics is working to obtain FDA clearance. Assuming that TriAgenics receives clearance, we then plan to conduct human clinical trials in order to have specific safety data to present before going to market. Following FDA clearance, our goal is to enter the dental market with first sales in 2025. Our business model is similar to Align Technology’s clear braces. Licensed dentists will send TriAgenics their patients’ x-rays and prescription for Zero3 TBA treatment. TriAgenics will then fabricate custom 3TBA guides and sell them to dentists for an estimated $350 per tooth bud treated.
THE PROBLEM & OUR SOLUTION
Eliminating Wisdom Teeth With Zero3 TBA Technology
Patients underestimate recovery time after having all wisdom teeth extracted. On average, patients miss 2.5 days of work or school because the surgical procedure is highly invasive. When wisdom teeth are allowed to form, they are the most likely teeth to be impacted. This makes them prone to trapping food and bacteria, leading to repeated, expensive treatment later in life. More than 5 million patients in the U.S. spend over $3 billion annually on wisdom teeth extractions or treatments, and more than 80% of all wisdom teeth eventually need to be removed. Zero3 TBA has the potential to prevent the pain, cost, and recovery time associated with wisdom teeth extractions (Source | Source).
We believe Zero3 TBA will deliver better lifelong outcomes for the patient. This minimally invasive treatment is designed to prevent wisdom teeth from ever forming and it is expected to eliminate common complications following wisdom teeth extraction. The treatment takes just 60-90 seconds per tooth bud treated, with the overall procedure estimated at 30 minutes start to finish to treat four tooth buds on one child, and is designed to be easy for dentists to deliver.
the market & Our Traction
A $2.5 Billion Market Opportunity With Our Advanced Technology
We estimate the total addressable market for TriAgenics’ Zero3 TBA products to be more than $2.5 billion annually. U.S. consumers spend more than $3 billion every year for wisdom tooth extractions and treatment of secondary problems caused by wisdom teeth (Source). More than 80% of wisdom teeth are impacted or do not erupt normally, causing significant dental infections and pain (Source). More than 80% of all wisdom teeth will need to be removed.
We believe TriAgenics is on the brink of revolutionizing dental health with our Zero3 TBA technology. We aim to become the new standard of care for managing wisdom teeth within 10 years of our introduction. Zero3 TBA is a high-precision, minimally invasive procedure designed to eliminate the common complications associated with having wisdom teeth extracted, providing a safer and more effective alternative for kids and parents alike. The fully guided ablation cycle takes just 60 to 90 seconds per tooth bud treated (with the overall procedure estimated at 30 minutes start to finish for four tooth buds) and is designed to be easy for dentists to deliver. Zero3 TBA will be quick and is expected to have no significant recovery time or significant complications. Our founder is an experienced dentist who has successfully launched three startups in the past. We have received positive reactions from dentists, with oral surgeons and pediatric specialists contacting us to learn more about Zero3 TBA.
Why Invest
Disrupting the Wisdom Tooth Extraction Market
Invest in disrupting the wisdom tooth extraction market, where the total addressable market is estimated to be more than $2.5 billion annually. With 93% of all teenagers forming at least one wisdom tooth and over 80% of all wisdom teeth needing to be extracted, the demand for wisdom tooth extractions is significant (Source). Our technology provides an alternative solution for the 5 million patients who spend over $3 billion annually for wisdom tooth extractions and treatment of wisdom tooth problems.
Join us as we work to revolutionize the dental industry and prevent wisdom teeth from ever forming.
TriAgenics 17-B
9/6/24 and 9/11/24 – Benzinga has been compensated by TriAgenics. The rate paid by the issuer for this content through Benzinga costs $15,000.
ABOUT
HEADQUARTERS
525 SW Umatilla Ave, Suite 102
Redmond, OR 97756
WEBSITE
View Site
TERMS
Overview
PRICE PER SHARE
DEADLINE
Mar. 16, 2025 at 9:51 AM UTC
VALUATION
Breakdown
MIN INVESTMENT
MAX INVESTMENT
OFFERING TYPE
Maximum Number of Shares Offered subject to adjustment for bonus shares
ALL UPDATES
02.24.25
Four Additional European Patents Granted
We are delighted to announce that Germany, France, Italy, and the United Kingdom have granted a patent for TriAgenics’ ablation probe system.
We now have 37 patents that protect TriAgenics' Zero3 TBA treatment and technology across the U.S., Australia, Canada, Mexico, and a growing number of European nations.
Click here for a comprehensive list of TriAgenics patents.
This is an exciting time made possible by your support.
Thank you!
01.22.25
510(k) Application Submitted
We are excited to share that TriAgenics submitted its 510(k) application to the U.S. Food and Drug Administration in December.
The 510(k) clearance process involves a comprehensive review of our Zero3 TBA micro-ablation system’s safety and performance data. The FDA will use this information to determine if the technology our system uses is "substantially equivalent" to devices the administration has previously approved.
On average, obtaining 510(k) clearance takes 6 months, but it can take longer depending on inquiries the FDA may have.
Stay tuned — and thank you again for joining our shareholder community. With your support, we march forward with confidence that federal clearance is just over the horizon.
The TriAgenics Team
11.15.24
We’ve Reached Our Goal!
Dear TriAgenics Community,
We are excited to announce that TriAgenincs’ StartEngine raise has reached its goal four days before the close date! Thanks to more than 1,580 investors — and a flurry of investment activity in recent days — we have officially reached $5 million raised.
We’re thrilled that you have joined our shareholder community and we send a hearty thank you for believing in our product and our mission. Together, we have the potential to reshape preventive dental care and vastly improve oral health around the globe.
More than 5,200 StartEngine investors chose to follow our campaign. What a crowd! For those of you who were planning to invest but missed the chance, there is still time to get on our waiting list. This opportunity ends on Monday at midnight, so be sure to act now.
As a shareholder, you play a vital role. Your commitment is instrumental in paving the path for our success. As we celebrate this milestone, we're also gearing up to work harder than ever to realize our future goals.
Thank you for your trust and partnership on this exciting journey!
The TriAgenics Team
11.14.24
Invest in Dental Innovation — Just 4 Days Left
Dear TriAgenics Community,
As we charge toward our goal, remaining shares are going fast. More than 5,200 StartEngine investors have added our raise to their watchlists. If they make their move today, you could miss out on a great opportunity.
Whether you’re looking to make your first investment in TriAgenics or add to your existing shares, now is the time to act. This is your chance to get in early and reshape an industry worth billions.
Dental professionals need a non-invasive way to deal with wisdom teeth — and parents are demanding one. We developed Zero3 TBA treatment to provide the solution.
Our Zero3 TBA treatment is a minimally invasive, high-precision procedure designed to prevent the growth of wisdom teeth. This approach eliminates the need for painful wisdom teeth surgery and it ensures a lifetime free of wisdom teeth problems.
Zero3 TBA Treatment Requires:
- No Sedation
- No Surgery
- No Stitches
- No Opioid Pain Medication
With just 4 days left, this unique investment opportunity is about to vanish.
Click now to claim your equity!
11.13.24
Our Roadmap: What Lies Ahead
Just 5 Days Left to Invest in TriAgenics
Dear TriAgenics Community,
Our Zero3 TBA treatment represents a significant breakthrough in preventative dental care. With its potential to reduce infections, eliminate dry sockets, and provide convenient and quick treatment, our Zero3 TBA system is poised to revolutionize the way dentists manage troublesome wisdom teeth.
We believe Zero3 TBA will be the new standard of care by 2030, and we are working tirelessly to bring our new product to market.
What Lies Ahead
🔹 FDA 510(k) Clearance: We’ve been working vigorously to prepare our FDA 510(k) application, with the goal to submit by mid-December.
🔹 Market Analysis: We have developed a detailed marketing plan designed for a successful product roll-out in 2025. Consumer focus groups, brand asset development, sales team onboarding, creation of educational materials, and more are just over the horizon.
🔹 Manufacturing Scale-Up: We are actively working with manufacturing partners in anticipation of high demand for Zero3 TBA systems and custom treatment kits following FDA clearance.
The Future of Dental Care
We designed Zero3 TBA treatment to eliminate all pain and complications associated with wisdom teeth. As we continue our journey toward commercial launch, we’re looking forward to having you along for the ride.
Shares are going fast. Invest NOW!
11.12.24
Get a Piece of the Action - Just 6 Days Left
This Raise Ends Next Monday
November 18 marks the end of TriAgenics’ CF offering on StartEngine. If you’re thinking about adding MedTech to your portfolio, now is the time to act.
The Price is Right
🔹 Join TriAgenics' shareholder community for as little as $300.
🔹 Add additional shares for just $3 each.
🔹 Investors who contribute $25K or more receive 5% bonus shares.
🔹 Eligible StartEngine Venture Club members receive a 10% bonus for any shares they purchase during this offering.
Time is Running Out
Our StartEngine offering closes in just 6 days - and shares are going fast. Don’t miss this opportunity to invest in the future of wisdom teeth care. Join the TriAgenics movement today!
11.11.24
1 Week Left to Invest in TriAgenics
Dear TriAgenics Community,
This is it – we’re down to the final 7 days of our campaign. The opportunity to invest in TriAgenics is rapidly closing. This is your chance to own MedTech stock and usher in change that has real meaning — a way to avoid wisdom teeth surgery.
An Important Investment
At TriAgenics, we’ve always been driven by a bold vision: to create a safe, fast, and effective way to prevent troublesome wisdom teeth from ever forming. The goal was to develop a treatment designed to eliminate all complications associated with third molars – and we’ve done it.
Our Zero3 TBA system is not a prototype; it’s the result of more than a decade of innovation, engineering breakthroughs, and relentless determination.
We're Gaining Speed
🔹 More than $12 million raised and backed by thousands of investors who share our vision for the future.
🔹 Growing interest from dental practitioners, dental networks, and dental schools.
🔹 On target to submit for FDA approval next month.
🔹 32 U.S. and international patents granted for both our treatment and technology.
Get In Now
With only one week left, this is the time to make your move. Our final stretch is where most funds are raised, and we’re gaining serious momentum. Join us, and let’s finish this campaign strong together.
Get Your Equity!
11.10.24
Why Invest Now? Just 8 Days Left!
Dear TriAgenics Community,
As we enter the final stretch of our StartEngine campaign, now is the perfect moment to become a shareholder. With just 8 days left, this is your opportunity to invest in the future of dentistry and be part of a revolution designed to eliminate wisdom teeth trauma.
WHY INVEST NOW?
A Visionary Future: TriAgenics intends to transform preventive dental care with its cutting-edge Zero3 TBA technology. Our vision is clear: Introduce a treatment designed to prevent all health issues associated with wisdom teeth. We’ve completed R&D, and your investment will help us enter a growing dental market with this exciting new technology.
Solid IP Position: Since this raise began, 9 new patents have issued. We now have 32 U.S. and international patents that protect our treatment and technology. With your support, we have the potential to make Zero3 TBA the new standard of care across the globe.
Catch the Wave: The global dental market is forecast to double in size by 2032, and TriAgenics is positioned to be a leader in this space. Dentists need a better way to manage painful wisdom teeth, and we have the solution. Our non-invasive treatment is the first of its kind. Investing in TriAgenics places you at the forefront of this once-in-a-lifetime market growth.
Don’t Miss Out on Exclusive Investor Benefits
For investors who join us before the campaign closes, we’re offering exclusive perks, including:
- The Loyalty Bonus – Existing shareholders of TriAgenics who make an additional investment in this round and authorize TriAgenics to give their contact information to StartEngine will receive 10% bonus shares.
- Venture Club Bonus – TriAgenics offers 10% additional bonus shares for all investments committed by investors that are eligible for the StartEngine Venture Club.
- Amount Based Perks – Invest $25,000+ and receive 5% bonus shares. Invest $100k+ and receive 10%.
ALL ABOARD
This is your chance to invest in TriAgenics through StartEngine and help bring wisdom teeth treatment into the modern age. Don’t let this opportunity slip away.
With just 8 days left, the window is closing fast.
INVEST NOW!
11.09.24
Recovery Takes Weeks. Investing Takes Seconds.
When we asked OpenAI's popular chatbot, ChatGPT, how long it takes to fully recover after wisdom teeth surgery, it said 3-6 weeks! It also recommends a week-long soft food diet while your gums heal. Sound fun to you?
It doesn't take artificial intelligence to know that wisdom teeth extraction can be a traumatic form of care. Oral surgeons and dentists want a less-invasive solution for their patients – and parents are demanding one. This is why we developed Zero3 TBA treatment and why we ask for your support.
With just 9 days remaining in our StartEngine raise – now is the time to invest in TriAgenics.
This is your opportunity to shape the future of dental care in just seconds and claim equity along the way.
REASONS TO INVEST
- Affordable Shares – Invest now for as little as $300. Add more shares for just $3 each!
- No More Extractions – TriAgenics is developing a quick, in-office procedure that prevents wisdom teeth from ever forming — no stitches or significant recovery time required.
- Patented Tech and Prior Funding – TriAgenics has previously raised more than $12 million and holds 32 patents, which protect its technology across the U.S., Australia, Mexico, Canada, and Europe.
- Solid Leadership – Dr. Leigh Colby (CEO) is a multiple entrepreneur with three successful startups under his belt and all are still in operation today.
Become a TriAgenics shareholder now. Just 9 Days Remain!
11.08.24
Rising Investment in Dental Tech
Just 10 Days Left - Claim Equity in TriAgenics' Dental Technology
According to a recent article published by Becker’s Dental, venture capital funding in the oral health AI and machine learning sector has swelled over the last decade, increasing from $5 million for one deal in 2014 to more than $145 million for eight deals so far in 2024.
Several other types of dental technology companies have also received large investments this year. Three have received investments totaling more than $580 million since September of 2024 alone (Read more).
DENTAL INNOVATION - A DRIVING FACTOR
Dental innovation is attracting investor interest as companies continue to push the tech needle. The goal is to give dental professionals advanced tools designed to provide new and enhanced treatments that lead to improved health outcomes and better overall experiences for patients.
TriAgenics is part of this trend with the development of its fully guided micro-ablation system, a new technology designed to eliminate all complications associated with surgical extraction of wisdom teeth.
With just 10 days remaining in TriAgenics’ current StartEngine raise - now is the time to add dental tech to your portfolio.
Get in on the ground floor with TriAgenics for just $3 per share.
Join our shareholder community today.
REWARDS
JOIN THE DISCUSSION
0/2500
Dorothy Harry
4 months ago
Thank you for the information Mr Colby. I'm looking forward to it. BTW I heard about this from my daughter who is a Professor at our local community college as an instructor in the Dental Assisting program and is working toward dental school
Show more
1
0
Dorothy Harry
4 months ago
Do you have an anticipated date that additional shares will be offered?
1
0
Edward Zawacki
4 months ago
Hello, Do you have any updates on the FDA approval process? Thanks!!
Show more
1
0
Jerry Irwin
5 months ago
Great update and looking forward to fantastic growth ahead; just keep focusing intently on what Teddy Roosevelt yelled at the Rough Riders as they stormed up San Juan Hill: Charge, boys, charge!
Show more
0
0
Ajay Dand
6 months ago
What is the current time lime to start human trials and how long are they expected to last?
0
0
fabio weiss ferreira chaves
6 months ago
Hi there, glad to be part of the TriAgenics journey! Assuming that the technology gets approved for use in humans, I have two questions: 1. Do you envision that a pediatric dentist would make a referral to an oral surgeon for treatment with Zero3 TBA? 2. Will Zero3 TBA be available to non-oral surgeon practitioners? Thanks!
Show more
1
0
Barrington Carter
7 months ago
Absolutely thrilled to be part of the TriAgenics journey from the start! Witnessing the Zero3 Tooth Bud Ablation technology evolve from concept to a tangible solution has been nothing short of inspiring. The potential to eliminate wisdom teeth extractions and the associated pain and complications is revolutionary. As an early investor, I'm incredibly proud and optimistic about the future. TriAgenics is poised to transform oral health, and I'm eagerly anticipating the positive impact this innovation will have on countless lives.
Show more
1
0
Garrick Thornton
9 months ago
is this treatment covered by insurance companies? If not now are you lobbying a relationship from them?
Show more
3
0
Olivier Wullen
9 months ago
Hi, Dental insurance coverage will be crucial for general adoption of the Zero3 TBA technology. USD 1400 per child is a lot of money for a preventive treatment. What percentage of the 6-12 year old children have dental insurance in the US?
Show more
1
0
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
FAQS
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000 are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, they are limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancellation period. Once the four-hour window has passed, it is up to each company to set their own cancellation policy. You may find the company’s cancellation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Dorothy Harry
4 months ago
Thank you, I will tell her. She is very driven!
0
0